Trial Profile

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms DOL-ART
Sponsors ViiV Healthcare

Most Recent Events

31 Oct 2018 Final results presented at the 14th International Congress on Drug Therapy and HIV Infection
27 Oct 2017 Results of 2nd interim analysis (data cut 27 months after last patient in) assessing safety and efficacy presented at the 16th European AIDS Conference
23 Oct 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com